Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.44 USD
Change Today 0.00 / 0.00%
Volume 186.9K
OXGN On Other Exchanges
As of 2:08 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

oxigene inc (OXGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/22/14 - $3.07
52 Week Low
05/7/15 - $1.31
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for OXIGENE INC (OXGN)

oxigene inc (OXGN) Related Bloomberg News

View More Bloomberg News

oxigene inc (OXGN) Related Businessweek News

No Related Businessweek News Found

oxigene inc (OXGN) Details

OXiGENE, Inc., a biopharmaceutical company, focuses on the development of vascular disrupting agents to treat cancer in the United States. Its principal clinical stage product includes fosbretabulin tromethamine, a reversible tubulin binding agent, which has completed Phase II clinical trial for treating recurrent ovarian cancer; and in Phase II clinical trial for treating gastrointestinal neuroendocrine tumors. The company also develops OXi4503 for patients with relapsed or refractory acute myelogenous leukemia or myelodysplastic syndromes. OXiGENE, Inc. was founded in 1988 and is headquartered in South San Francisco, California.

13 Employees
Last Reported Date: 03/30/15
Founded in 1988

oxigene inc (OXGN) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: $309.7K
Chief Scientific Officer and Director
Total Annual Compensation: $447.2K
Compensation as of Fiscal Year 2014.

oxigene inc (OXGN) Key Developments

OXiGENE Mulls Acquisitions

OXiGENE, Inc. (NasdaqCM:OXGN) filed a shelf registration in the amount of $75 million and intends to use the net proceeds for its operations and for other general corporate purposes, including, but not limited to, its internal research and development programs and the development of new technologies, general working capital and possible future acquisitions.

OXiGENE, Inc. Announces Management Changes

OXiGENE, Inc. announced the appointment of a new President and Chief Executive Officer, Bill Schwieterman, M.D. The company's current CEO, Dai Chaplin, Ph.D., will become Chief Scientific Officer. Both Drs. Schwieterman and Chaplin will continue to serve on OXiGENE's board of directors. Dr. Schwieterman is an experienced biotechnology executive with a deep background in clinical development and regulatory matters. From 2009 to 2014, he was Chief Medical Officer of Chelsea Therapeutics, Inc. Dr. Schwieterman was formerly Chief of the Medicine Branch and Chief of the Immunology and Infectious Disease Branch in the Division of Clinical Trials at the Food and Drug Administration.

OXiGENE, Inc. Reports Unaudited Financial Results for the First Quarter Ended March 31, 2015; Announces Phase I/Ii Study of OXi4503 and AML for the Remainder of 2015

OXiGENE, Inc. reported unaudited financial results for the first quarter ended March 31, 2015. At March 31, 2015, the company had cash of $36 million, compared to $30 million at December 31, 2014. For the quarter ended March 31, 2015, the company reported a net loss of $2.8 million compared to a net loss of $2.6 million for the comparable period in 2014. The increase of $0.2 million in the net loss in the first quarter of 2015 as compared to the first quarter of 2014 was due primarily to increased research and development (R&D) expenses. Loss from operations was $2,777,000 against $2,628,000 last year. Net loss and comprehensive loss was $2,772,000 or $0.13 per basic and diluted share against $2,630,000 or $0.29 per basic and diluted share last year. For the remainder of 2015, the company anticipates several important milestones. The company plans to start enrollment to the company-sponsored Phase I/II study of OXi4503 and AML. The company anticipates completing enrollment in the ongoing Phase II study of fosbretabulin in GI-NETs and to see preliminary results in the study. The company expects to obtain definitive U.S. regulatory guidance of a potential design and scope of a late stage development program for fosbretabulin in ovarian cancer. The company also anticipates a public presentation later this year on the ongoing PAZOFOS study, which is being conducted in the U.K. The company expects that the Phase Ib dose escalation part of the study will be completed later this year. The company also expects an update on the study to be provided by the investigators at the European Society of Gynecological Oncology, ESGO.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXGN:US $1.44 USD 0.00

OXGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OXGN.
View Industry Companies

Industry Analysis


Industry Average

Valuation OXGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OXIGENE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at